The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
Pediatric patients within the specified age range.
Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test.
Presentation for treatment within the early symptomatic phase of influenza illness.
Presence of fever and at least one respiratory symptom.
Clinical signs suggestive of severe or complicated influenza infection
requiring inpatient management.
Presence of a concurrent bacterial infection requiring systemic therapy.
Significant immunocompromised, or severe/uncontrolled comorbid conditions.